SCHEMBL15345012

SCHEMBL15345012

Cc1ccc2nc(C)n([C@@H]3CCN(C(C)C)C3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.42
CCR5 P51681 2/20 0.42
CYP11B2 P19099 1/20 0.42
CDK9 P50750 2/20 0.40
CCNT1 O60563 1/20 0.40
HRH3 Q9Y5N1 5/20 0.39
KCNH2 Q12809 1/20 0.38
MCHR1 Q99705 3/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
GFER P55789 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 1/20 0.37
DYRK1A Q13627 2/20 0.36
CLK1 P49759 1/20 0.36
DYRK2 Q92630 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
HTR3A P46098 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15341823 0.88 CCR5 (0.43) CYP2D6CCR5CDK9CCNT1HRH3
SCHEMBL15344961 0.83 CYP2D6 (0.44) CYP2D6CCR5CYP11B2CDK9CCNT1
SCHEMBL15345119 0.83 CYP2D6 (0.44) CYP2D6CCR5CYP11B2CDK9CCNT1
SCHEMBL17678354 0.80 CYP11B2 (0.58) CYP11B2CDK9CCNT1MCHR1KDM4E
SCHEMBL15345132 0.80 CYP11B2 (0.49) CYP2D6CCR5CYP11B2CDK9CCNT1
SCHEMBL15345133 0.77 CYP11B2 (0.49) CYP11B2CDK9CCNT1KCNH2MCHR1
SCHEMBL15344929 0.76 CYP11B2 (0.45) CYP2D6CCR5CYP11B2CDK9CCNT1
SCHEMBL15344938 0.74 CYP11B2 (0.45) CYP11B2CDK9CCNT1MCHR1KDM4E
SCHEMBL15341758 0.73 CCR5 (0.46) CYP2D6CCR5CDK9CCNT1KDM4E
SCHEMBL15341825 0.73 CCR5 (0.46) CYP2D6CCR5CDK9CCNT1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CYP2D6 302/4885CCR5 3/4885CYP11B2 19/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CYP2D6 302/4885CCR5 3/4885CYP11B2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.